Last reviewed · How we verify

Glasdegib IV infusion

Pfizer · Phase 1 active Small molecule Quality 15/100

Glasdegib IV infusion is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.

At a glance

Generic nameGlasdegib IV infusion
SponsorPfizer
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glasdegib IV infusion

What is Glasdegib IV infusion?

Glasdegib IV infusion is a Small molecule drug developed by Pfizer.

Who makes Glasdegib IV infusion?

Glasdegib IV infusion is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is Glasdegib IV infusion in?

Glasdegib IV infusion is in Phase 1.

What are the side effects of Glasdegib IV infusion?

Common side effects of Glasdegib IV infusion include Nausea, Febrile neutropenia, Anaemia, Diarrhoea, Pyrexia, Platelet count decreased.

Related